CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Carbaryl

甲萘威 杂质对照品Carbaryl Impurities

7 个杂质条目7 impurity entries

本页汇总 甲萘威 的 7 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 7 impurity reference standards of Carbaryl. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 甲萘威(Carbaryl)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesHydrolysis of carbaryl by carbonate impurities in reference clay SWy-2
    Journal of agricultural and food chemistry · 2004 · Arroyo LJ et al.  ·  PMID 15612797  ·  DOI
  2. 杂质研究Impurity studiesCytotoxicity and genotoxicity of methomyl, carbaryl, metalaxyl, and pendimethalin in human umbilical vein endothelial cells
    Journal of applied toxicology : JAT · 2021 · Saquib Q et al.  ·  PMID 33427323  ·  DOI
  3. 杂质研究Impurity studiesPassivated graphene quantum dots for carbaryl determination in juices
    Journal of separation science · 2021 · Soriano ML et al.  ·  PMID 33527734  ·  DOI
  4. 分析方法Analytical MethodsSimultaneous determination of carbendazim and carbaryl pesticides in water bodies samples using a new voltammetric sensor based on Moringa oleifera biochar
    Chemosphere · 2024 · Silva JOS et al.  ·  PMID 37972866  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisChemical synthesis of the carbaryl metabolite trans-5,6-dihydro-5,6-dihydroxy-1-naphthyl methylcarbamate
    Journal of agricultural and food chemistry · 1972 · Richey FA Jr et al.  ·  PMID 5054391  ·  DOI

甲萘威 —— 原料药与杂质对照品Carbaryl — drug substance & impurities

共 7 个条目(含原料药本体)7 items incl. the drug substance
Carbaryl Impurity 5 structure
5
甲萘威杂质5Carbaryl Impurity 5
Carbaryl Impurity 5
CAS No.2619-00-3
Chemical FormulaC13H13NO2
Purity>95%现货In stock
10mg25mg50mg100mg
Carbaryl Impurity 7 structure
7
甲萘威杂质7Carbaryl Impurity 7
Carbaryl Impurity 7
CAS No.4089-04-7
Chemical FormulaC12H11NO2
Purity>95%现货In stock
10mg25mg50mg100mg
Carbaryl Impurity 8 structure
8
甲萘威杂质8Carbaryl Impurity 8
Carbaryl Impurity 8
CAS No.5266-96-6
Chemical FormulaC12H11NO3
Purity>95%现货In stock
10mg25mg50mg100mg
Carbaryl Impurity 9 structure
9
甲萘威杂质9Carbaryl Impurity 9
Carbaryl Impurity 9
CAS No.24305-26-8
Chemical FormulaC12H11NO4
Purity>95%现货In stock
10mg25mg50mg100mg
Carbaryl Impurity 10 structure
10
甲萘威杂质10Carbaryl Impurity 10
Carbaryl Impurity 10
CAS No.32263-74-4
Chemical FormulaC12H11NO3
Purity>95%现货In stock
10mg25mg50mg100mg
Carbaryl Impurity 11 structure
11
甲萘威杂质11Carbaryl Impurity 11
Carbaryl Impurity 11
CAS No.32263-67-5
Chemical FormulaC12H11NO3
Purity>95%现货In stock
10mg25mg50mg100mg
Carbaryl Impurity 12 structure
12
甲萘威杂质12Carbaryl Impurity 12
Carbaryl Impurity 12
CAS No.146074-42-2
Chemical FormulaC12H11NO3
Purity>95%现货In stock
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

甲萘威 —— 研究文献与合成路线Carbaryl — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 甲萘威 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Carbaryl. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Compartmentalization of the Carbaryl Degradation Pathway: Molecular Characterization of Inducible Periplasmic Carbaryl Hydrolase from Pseudomonas spp
    Kamini, Shetty D, Trivedi VD, et al. · Applied and environmental microbiology · 2018 · 被引 22cited 22
  2. Carbaryl residue concentrations, degradation, and major sinks in the Seto Inland Sea, Japan
    Derbalah A, Chidya R, Kaonga C, et al. · Environmental science and pollution research international · 2020 · 被引 13cited 13
  3. Heterologous expression and exploration of the enzymatic properties of the carbaryl hydrolase CarH from a newly isolated carbaryl-degrading strain
    Ke Z, Zhu Q, Jiang W, et al. · Ecotoxicology and environmental safety · 2021 · 被引 10cited 10
  4. Characterization of carbaryl-degrading strain Bacillus licheniformis B-1 and its hydrolase identification
    Hu K, Wang X, Zhu J, et al. · Biodegradation · 2020 · 被引 10cited 10
  5. Two LysR Family Transcriptional Regulators, McbH and McbN, Activate the Operons Responsible for the Midstream and Downstream Pathways, Respectively, of Carbaryl Degradation in Pseudomonas sp. Strain XWY-1
    Ke Z, Zhu Q, Gao S, et al. · Applied and environmental microbiology · 2022 · 被引 8cited 8
  6. Metabolic engineering of <i>Pseudomonas bharatica</i> CSV86<sup>T</sup> to degrade Carbaryl (1-naphthyl-<i>N</i>-methylcarbamate) via the salicylate-catechol route
    Malhotra H, Dhamale T, Kaur S, et al. · Microbiology spectrum · 2024 · 被引 5cited 5

合成与制备工艺专利Synthesis & process patents

  1. Preparation of carbaryl and methyl parathion universal antibody and universal envelope antigen
    JIALONG SUN · 公开号 CN101475637CN101475637 · 2009

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

甲萘威 杂质谱研究要点Carbaryl — impurity profiling notes

下面这些是拿到 甲萘威 的 7 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 7 impurity entries for Carbaryl, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances